Summary
- Profile Type
- Technology offer
- POD Reference
- TOTR20240430012
- Term of Validity
- 30 April 2024 - 30 April 2025
- Company's Country
- Turkey
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A group of researchers from a reputable university based in Izmir-Türkiye has developed an enzymatic-based immunosensor based on the amperometry technique that can sensitively, selectively and rapidly determine the SARS-CoV-2 S1 protein for the diagnosis of COVID-19. The product is a diagnostic kit and has a TRL of 4. Licensing thorugh commercial agreement is sought.
- Full Description
-
There are diagnostic tests developed based on different techniques for the diagnosis of COVID-19. PCR (Polymerase Chain Reaction) tests are a method widely used in the diagnosis of COVID-19 and approved by the FDA and other health regulatory agencies. Commercialized, automated systems are available and are usually performed in a laboratory setting. Antigen tests are designed to provide rapid diagnosis of COVID-19. Many antigen tests come in a test strip format that is used to obtain rapid results. These tests are used particularly in situations where rapid results are required.
They are commercialized and distributed internationally, but are not as common as PCR tests. Antibody tests are used to detect a person's antibodies to COVID-19. They can be used to assess immune status after infection or to determine contact with COVID-19. Although many antibody tests have been introduced, they have some limitations in terms of sensitivity and specificity. Immunosensors are analytical devices that can detect biological molecules (usually such as antibodies or antigens) and measure the presence or concentration of these molecules.
The invention is an enzymatic-based immunosensor based on the amperometry technique that can sensitively, selectively and rapidly determine the SARS-CoV-2 S1 protein for the diagnosis of COVID-19. The invention is based on the measurement of the reaction between SARS-CoV-2 S1 protein and its specific antibody on the disposable electrode surface by amperometry technique and has an application in artificial saliva. With the immunosensor based on the enzymatic-based amperometric method developed within the scope of the invention, SARS-CoV-2 protein determination can be performed in a low-cost, fast, easy-to-use, suitable for bedside use, reliable and sensitive manner during point of care/on-site diagnosis.
With the enzymatic-based amperometric immunosensor developed within the scope of the invention, SARS-CoV-2 S1 protein determination can be performed in a low volume such as 10 μL. In addition, the preparation time of the developed immunosensor is 5 hours and the analysis time is 2.5 minutes. The invention relates to the sector for diagnostic kits in the field of biotechnology. During the application of the inventive immunosensor to the diagnostic kit, its integration into the handheld device was carried out. Therefore, COVID-19 determination can be performed in a handheld, easy-to-apply and suitable for point of care/on site use. Thus, compared to the currently known methods, reliable, sensitive and selective determination of SARS-CoV-2 will be possible. The enzymatic immunosensor based on the amperometry technique developed within the scope of the invention is at TRL 4 level and prototype development has been carried out at laboratory level.
It can be said that the developed immunosensor is commercially applicable. In this context, we are looking for commercial agreements with technical assistance with route-to-market companies in the biotechnology, medical, biomedical and engineering sectors. With the developed immunosensor, it aims to establish numerous partnerships and licensing agreements in various biotechnology, medical, biomedical and engineering sectors globally. In this way, with the immunosensor developed, SARS-CoV-2 protein determination can be performed in the market during point of care/on-site diagnosis in a low-cost, fast, easy-to-use, suitable for bedside use, reliable and sensitive manner. - Advantages and Innovations
- With the immunosensor based on the enzymatic-based amperometric method developed within the scope of the invention, SARS-CoV-2 protein determination can be performed in a fast, sensitive, selective, reliable, easy and low-cost manner. During the application of the inventive immunosensor to the diagnostic kit, its integration into the handheld device was carried out. Therefore, COVID-19 determination can be performed in a handheld, easy-to-apply and suitable for point of care/on site use. In addition, the enzymatic-based immunosensor developed within the scope of the invention has an application in artificial saliva environment. In this context, it is possible to perform SARS-CoV-2 protein determination by non-invasive method.
- Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
- Expected partner is a diagnostic kit manufacturer from private sector who is willing to license and adopt the mentioned technology to their products.
- Type and Size of Partner
- SME 11-49SME 50 - 249SME <=10Big company
- Type of partnership
- Commercial agreement with technical assistance
Call details
- Coordinator required
-
Yes
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis06001018 - Virus, Virology/Antibiotics/Bacteriology
- Market keywords
- 05001001 - Diagnostic services
- Targeted countries
- All countries